9.05
+0.69(+8.25%)
Currency In USD
| Previous Close | 8.36 |
| Open | 8.44 |
| Day High | 9.13 |
| Day Low | 8.41 |
| 52-Week High | 19.93 |
| 52-Week Low | 5.41 |
| Volume | 3M |
| Average Volume | 1.63M |
| Market Cap | 785.51M |
| PE | -4.02 |
| EPS | -2.25 |
| Moving Average 50 Days | 7.31 |
| Moving Average 200 Days | 7.18 |
| Change | 0.69 |
If you invested $1000 in Kura Oncology, Inc. (KURA) 10 years ago, it would be worth $646.43 as of September 29, 2025 at a share price of $9.05. Whereas If you bought $1000 worth of Kura Oncology, Inc. (KURA) shares 5 years ago, it would be worth $296.24 as of September 29, 2025 at a share price of $9.05.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kura Oncology and Kyowa Kirin Announce Publication of Pivotal Ziftomenib Data in Relapsed/Refractory NPM1-Mutated AML in the Journal of Clinical Oncology
GlobeNewswire Inc.
Sep 25, 2025 9:18 PM GMT
– KOMET-001 in R/R NPM1-m AML met its primary endpoint with ziftomenib monotherapy demonstrating significant clinical benefit and deep responses – – Consistent activity across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, lines
Kura Oncology to Participate in Upcoming Investor Conference
GlobeNewswire Inc.
Sep 24, 2025 11:30 AM GMT
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is s
Kura Oncology Highlights Preclinical Data Demonstrating Potential of Farnesyl Transferase Inhibitors to Overcome Drug Resistance in Combination with Key Targeted Therapies Across Multiple Tumor Types
GlobeNewswire Inc.
Sep 16, 2025 8:01 PM GMT
Analyst/Investor event showcases opportunities for KO-2806 (darlifarnib) in combination with PI3Kα inhibitors, KRAS inhibitors and antiangiogenic tyrosine kinase inhibitors (TKIs) Preliminary clinical data and KO-2806 development plans to be presente